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Background. Idiopathic Pulmonary Fibrosis (IPF) is a fatal lung disease of unknown etiology characterized by interstitial ﬁbrosis
determining irreversible distortion of pulmonary architecture. Reactive oxygen species (ROS) and markers of oxidative stress play
a pivotal role in human IPF pathology, possibly through induction of epithelial-mesenchymal transition (EMT). Methods.W e
investigated by immunohistochemistry, in UIP and COP tissue samples, the expression of most relevant markers of the molecular
interplayinvolvingRAGE,oxidant/antioxidantbalanceregulation,tissuenitrosylation,andmediatorsofEMT.Results.I nbothUIP
and COP, the degree of RAGE expression was similarly high, while SODs and i-NOS, diﬀusely present in COP endoalveolar plugs,
were almost absent in UIP ﬁbroblast foci. A lower degree of tissue nitrosilation was observed in UIP than in COP. Conclusions.
Fibroblast lesionsof UIP and of COP share a similardegree ofactivation of RAGE, while antioxidantenzyme expression markedly
reduced in UIP.
1.Background
Idiopathic Pulmonary Fibrosis (IPF) is a progressive, fatal
lung disease of unknown etiology characterized by alveolar
wall ﬁbrosis determining a rapid decline of lung function.
The prognosis for IPF patients is poor, with a mean survival
of 3–5 years [1]. Histopathologically, IPF is characterized by
a speciﬁc pattern of parenchymal injury, deﬁned usual inter-
stitial pneumonia (UIP). The hallmarks of UIP are ﬁbroblast
foci (FF) [2], which represent both the diagnostic feature
and the sites of active disease progression. They consist of
parietal aggregates of activated ﬁbroblasts and myoﬁbrob-
lasts which promote excessive deposition of extracellular
connective matrix (ECM) in the pulmonary interstitium,
thusdetermining theinexorable progression ofﬁbrosis. Over
the last few years, growing evidence suggested that IPF may
betheresult ofsequentialacutelunginjury targeting alveolar
epithelial cells and of the consequent pathological wound-
healing response [3]. It has recently been proposed that
ﬁbroblasts in UIP may at least partially derive from alveolar
epithelial cells through epithelial-mesenchymal transition
(EMT) [4].
T h ep r e s e n c ea n dt h er o l eo fi n ﬂ a m m a t o r yc e l l si nU I P
has been controversial [5]. Although early theories on IPF
pathogenesis attributed to inﬂammatory cells a key role in
the disease, a recent paradigm shift focused on diﬀerent
factors inducing epithelial cell damage/reparation, among
which free radical-induced damage and changes in the
cellular oxidant/antioxidant balance [6] have a relevant role.
Reactive oxygen species (ROS) are normal byproducts
of O2 metabolism and have important roles in biological
processes. Excess ROS, such as those produced by tobacco
smoke, are recognized lung toxic factors and are associated
with the development of many diseases [7]. Nitric oxide
(NO◦), a messenger molecule with complex biological activ-
ities, interacts with ROS producing highly reactive nitrogen
intermediates. Both ROS and NO◦ levels in the lung are
regulated by cellular enzymatic activity: NO◦ synthesis is
catalyzed by nitric oxide synthase (NOS), in particular i-
NOS. Protection from free radicals is granted by diﬀerent2 Pulmonary Medicine
mechanisms, among which superoxide dismutases (SODs)
are the only enzymatic system decomposing superoxide rad-
icals to H2O2. There are three diﬀerent mammalian SODs:
intracellular copper-zinc SOD (CuZnSOD), mitochondrial
manganese SOD(MnSOD) and extracellular SOD(ECSOD)
[8, 9]. SODs have been detected in all classes of lung cells but
show signiﬁcant variability in cell-speciﬁc localization and
expression.
It has been shown that oxidant/antioxidant imbalance
can activate multiple molecular pathways that culminate in
the induction of EMT in target cells: ROS activate SMAD2
and MAPK signaling which are crucial mediators of EMT
[10]; on the other hand, NO◦ attenuates TGF-β1-induced
EMT in alveolar epithelial cells [11].
The activation of the receptor for advanced glycation
products (RAGE), a recently described member of the
immunoglobulin super-family of cell surface receptors, has
been shown to be involved in renal ﬁbrogenesis through
both TGF-β1-dependent and independent EMT activation
pathways [12, 13]. Recent interest has also grown on its
possible involvementin lung pathology,where RAGEis most
abundant at a biochemical level [14]. So far, RAGE has been
implicated in acute lung injury, and in pulmonary ﬁbrosis in
bleomycin rat models where it induces EMT in AEC [15].
The tightly interconnected molecular pathways linking
RAGE, NO, TGF-β1, ROS and SODs are summarized in
Figure 1, with references to speciﬁc studies for each link.
The present study was aimed at analyzing in UIP tissue
samples, and especially in ﬁbroblastic foci, the expression
of the most relevant markers of the complex molecular
interplay involving RAGE, the enzymes regulating the oxi-
dant/antioxidant imbalance and tissue nitrosilation, and
mediators of EMT. To assess the speciﬁcity of the expression
patterns observed in UIP, the results were compared with
thoseobtainedincryptogenicorganizingpneumonia(COP),
an idiopathic lung disease characterized by deposition of
ﬁbroblasts and connective tissue, which however carries
a favorable prognosis. We are aware that in situ protein
expression analysis through immunohistochemistry has a
number of limits: in particular the technique allows only a
rough quantiﬁcation of the intensity of protein expression
and a suboptimal deﬁnition of cellular localization. How-
ever, immunohistochemistry remains the only method to
correlate in vivo protein expression, tissue morphology and
cellular phenotype, in particular in human tissue samples,
where single cell-protein analyses can hardly be performed.
2.Materialsand Methods
2.1. Patients. The immunohistochemical study was per-
formed on lung samples obtained at video-assisted thora-
coscopy from 42 consecutive patients between 2000 and
2007,inwhichthehistopathologicalexaminationshowedthe
typical morphological features of either UIP (29 patients) or
COP(13pa ti en ts ).T h eﬁ n a ldi a gn os esofUIPa n dCOPw er e
based on the diagnostic criteria of the American Thoracic
Society/European Respiratory Society Consensus Classiﬁca-
tion System after evaluation of all clinical, laboratory, and
instrumental data [2, 16]. None of the patients received
treatment before surgery. The work was approved by the
InstitutionalEthics Committee.Allpatients underwentcom-
plete pulmonary function testing, measurement of carbon
monoxide transfer factor (TlCO), arterial blood gases at rest
and after exercise, chest X-ray and high resolution CT, and
serological screening for connective tissue disease.
2.2.Controls. Controlsamplesfortheimmunohistochemical
study were obtained from normal tissue areas of 8 surgical
lobectomy specimens taken from patients with lung cancer.
2.3.Immunohistochemistry. Theimmunohistochemical pan-
el comprised antibodies and antisera speciﬁc for RAGE,
MnSOD, ECSOD, i-NOS, nitrotyrosine (as an indirect index
of oxidative stress), p65 subunit of activated NF-κB, phos-
phorylated SMAD2 and SMAD3, as detailed in Table 1.F o u r
micrometer thick paraﬃn sections were incubated overnight
at 4◦C with primary antibodies, diluted as indicated (Dako
antibody diluent, DakoCytomation, Carpinteria, CA) in
Table 1. Optimal pretreatments are detailed in Table 1.T h e
reactions were revealed with the avidin-biotin-peroxidase
complex (Dako LSAB+ System, Dako), using diaminoben-
zidine tetrahydrochloride as chromogen substrate (Dako).
Each reaction set included positive controls as suggested by
the manufacturer and a negative control slide exclusively
incubated with the dilution buﬀer. All immunostained slides
were examined at light microscopy by two independent
observerswhorecordedthecelltypesexpressingeachantigen
and who semiquantitatively scored the intensity of protein
expression. Cell staining intensity was graded as follows: no
staining (0), weak (+), moderate (++), and intense (+++).
In case of disagreement, slides were reevaluated collectively
to obtain a ﬁnal agreement on the score.
3.Results
3.1. Epidemiologic Data. The mean age of UIP patients was
58.6 years (range 39–81); 25 of them were males and 4
females. The mean age of COP patients was 55.3 years (range
43–81); 9 of them were males and 4 females.
3.2. Usual Interstitial Pneumonia. RAGE expression was
globally increased in UIP lungs (Figures 2(a)–2(c)): type I
and especially type II alveolar pneumocytes were strongly
immunoreactive (Figure 2(b)), at the cytoplasmic and mem-
brane level,as well as bronchial epithelia, inﬂammatory cells,
and endothelia. In FF, both the epithelial component and
stromal ﬁbroblasts expressed RAGE; squamous metaplastic
cells of FF also expressed RAGE in their cytoplasm (Fig-
ure 2(c)).
MnSOD granular, mitochondrial immunoreactivity was
observed in type II alveolar pneumocyte and macrophage
cytoplasms (Figures 2(d)–2(f)). In FF, surface pneumocytes
showed the strongest reactivity, while MnSOD expression
in squamous metaplastic cell was less intense (Figure 2(f)).
Occasional ﬁbroblasts were weakly reactive.Pulmonary Medicine 3
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Figure 1:The ﬁgure showsthe complex interplay involvingRAGE, reactive oxygen and nitrogen species, antioxidants,proﬁbrotic cytokines,
and their signalling pathways, and, in red, the most relevant eﬀects of pathway activation. The molecules investigated in the present study
are coloured in blue. The numbers in square brackets refer to bibliography citations.
Table 1: Source, concentrations,and pretreatment conditionsofthe antibodies used in the immunohistochemicalassays.MWO:microwave
oven.
Name Source Clone Working dilution Pretreatment
RAGE Abcam, Cambridge, UK Goat polyclonal 1:4000 none
MnSOD Stressgen, Victoria, Canada Rabbit polyclonal 1:2000 MWO 750W 15 
ECSOD Stressgen, Victoria, Canada Rabbit polyclonal 1:400 MWO 750W 15 
i-NOS NeoMarkers, Fremont, CA, USA Rabbit polyclonal 1:200 MWO 750W 15 
Nitrotyrosin UpState, Billerica, MA, USA Rabbit polyclonal 1:800 MWO 750W 15 
NF-kB Santa Cruz Biotechnology, CA, USA Rabbit polyclonal 1:450 MWO 750W 15 
SMAD2 Chemicon, Billerica, MA, USA Rabbit polyclonal 1:2000 MWO 750W 15 
SMAD3 Abcam Rabbit polyclonal 1:100 MWO 750W 15 
ECSOD was also observed in inﬂammatory cells, type II
alveolar pneumocytes and in endothelia (Figures 2(g)–2(i)).
Insurface andmetaplasticepithelialcellsofFFtheexpression
w a sles ss tr on gth a ni ntype2pn eum ocyt es(Fi gur es2(h)and
2(i)). The stroma of FF was constantly negative.
i-NOS expression was mostly observed in medium and
small vessels (Figure 2(j)). Low degree of reactivity was
present in macrophages and type II alveolar epithelia (Fig-
ure2(k)),whileinFFmetaplasticsquamouscellsappearedto
be more reactive than overlying pneumocytes (Figure 2(l)).
Stromal cells were faintly positive.
Nitrotyrosine expression was diﬀuse in UIP lungs; a
stronger stain was observed in interstitial area inﬁltrated by
larger amounts of inﬂammatory cells (Figure 2(m))t h a ni n
the stroma of FF (Figure 2(n)), which was almost negative.
Epithelial accumulation of nitrotyrosine was also observed,
both in type II pneumocytes and in metaplastic squamous
cells of FF (Figure 2(o)).
In UIP, nuclear expression of the p65 component of
activeNF-κBwas limited tointerstitial lymphocytes andspo-
radic noninﬂammatory cells (Figure 3(a)). Nuclear SMAD2
expression was present in a large proportion of epithelial
cells, alveolar type I, type II, bronchial and metaplastic
squamous cells, and in ﬁbroblasts and myoﬁbroblasts of
FF (Figure 3(c)). SMAD3 expression, on the contrary, was
mostlycytoplasmic,withonlyscatteredcellsshowing nuclear
reactivity (Figure 3(e)). Score of immunohistochemical
expression are summarized in Table 2.4 Pulmonary Medicine
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Figure 2: RAGE (a)–(c), MnSOD (d)–(f), ECSOD (g)–(i), i-NOS (j)–(l), and nitrotyrosine (m)–(o) expression in UIP. Low power images
(a, d, g, j, m) show an overall high degree of protein expression in the lung tissue. In FF, RAGE (b) expression is observed in type II alveolar
pneumocytes and stromal cells, MnSOD (e) and ECSOD (h) are expressed in epithelial cells but not in ﬁbroblasts, i-NOS expression (k) is
present in inﬂammatory cells and, to a lower degree, in epithelia; the overall amount of nitrotyrosine is extremely low (n). In bronchiolar
basalmetaplasticcellsofsandwichﬁbroblastfoci,theexpressionofRAGE(c),MnSOD(f),andECSOD(i)islessstrongthanthatinoverlying
alveolar pneumocytes, while i-NOS (l) and nitrotyrosine (o) stain is negative in alveolar pneumocytes, but present in metaplastic cells.Pulmonary Medicine 5
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Figure3:ExpressionofsignaltransductionmediatorsinUIP(a,c,e)andinCOP(b,d,f).Inbothlesions,NF-κBexpressionisonlyobserved
in inﬁltrating lymphocytes (a, b), while phosphorylated SMAD2 is present in a large number of epithelial, inﬂammatory and mesenchymal
cells (c, d). SMAD3 is expressed in the nuclei of epithelial cells overlying FF in UIP (e), while diﬀuse cytoplasmic stain characterizes COP
ﬁbroblast plugs (f).
3.3. Cryptogenic Organizing Pneumonia. Strong expression
of RAGE was observed in hyperplastic pneumocytes and
stromal ﬁbroblasts of COP endoalveolar plugs, as well as
in inﬂammatory cells (Figure 4(a)). The same cells were
also reactive for MnSOD and ECSOD (Figures 4(c), 4(e)).
Strong diﬀuse MnSOD reactivity was observed in the tissue
due to epithelial and inﬂammatory cell expression; ECSOD
was also expressed on the extracellular matrix. i-NOS
was mostly expressed in vessels and macrophages; alveolar
epitheliaandstromal cellsexpressed lowerreactivity.Stromal
cells in OP ﬁbroblastic plugs expressed higher degrees of
MnSOD (Figure 4(c))E C S O D( F i g u r e4(e)), and of i-NOS
(Figure 5(a)) than ﬁbroblasts of UIP FF (Figures 4(d), 4(f),
and 5(b),r e s p . ) .
Nitrotyrosine deposition in the cellular and extracellular
components, including the stroma of ﬁbroblastic plugs,
reﬂected the degree of cell activation (Figure 5(c))a n di nt h e
stroma was deﬁnitely higher than in UIP FF (Figure 5(d)).
A large number of inﬂammatory and rare epithelial cells
showed nuclear expression of the p65 component of active
NF-κB( F i g u r e3(b)). Analogously to what was observed in
UIP, SMAD2 was expressed diﬀusely in the nuclei of epithe-
lial, stromal, and inﬂammatory cells (Figure 3(d)), while
SMAD3 expression was observed only at the cytoplasmic
level (Figure 3(f)). See Table 2.
3.4. Normal Lung. MnSOD expression was limited to
bronchial epithelia and macrophages; smooth muscle cells
of bronchiolar walls showed some granular reactivity. Low
degrees of ECSOD expression were observed in all cellular
compartments and in the extracellular matrix. i-NOS was
expressed in endothelia, arterial walls and macrophages.
Inﬂammatory cells were the only site of nitrotyrosine depo-
sition. As far as signal transduction proteins were concerned,
SMAD2 nuclear expression was found in most epithelial
and inﬂammatory cells, while SMAD3 expression was only
cytoplasmic. No NF-κB expression was observed in normal
lung samples (Data not shown).6 Pulmonary Medicine
Table 2: Proﬁle and score of immunohistochemicalexpression in relevant lung cell types.
Type
Ip n
Type
II pn
Bronchiolar
epithelial
UIP ﬁbroblast foci COP endoalveolar plugs Macrophages
Overlaying
pneumocytes
Squamous
metaplastic
cells
Fibroblasts Reactive
pneumocytes Fibroblasts
RAGE + +++ + +++ +++ +++ +++ +++ +++
MnSOD − +++ ++ +++ ++ − +++ + +++
ECSOD − +++ + ++ + − ++ ++ +++
i-NOS − + − ++ + − + + +++
Nitrotyrosine − ++ − ++ ++ − ++ ++ +++
NF-kB − − − −− −−−−
P h - S M A D 2 + + + ++ ++++
SMAD3 − +∗ − + −−++∗ +∗ +∗
∗Cytoplasmic expression.
COP
RAGE
(a)
UIP
(b)
MnSOD
(c) (d)
ECSOD
(e) (f)
Figure 4: Comparison between organizing pneumonia ﬁbroblast plugs (a, c, e) and UIP FF (b, d, f). RAGE expression is strong in both
lesions, in epithelial and mesenchymal cells (a, b). MnSOD (c, d) and ECSOD (e, f) expression is stronger in COP, where it is present in
epithelial and mesenchymal cells, than in UIP, where only epithelial cells are immunoreactive.Pulmonary Medicine 7
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Figure 5: Comparison between organizing pneumonia ﬁbroblast plugs (a, c) and UIP FF (b, d). Higher i-NOS expression is present in
COP (a) than in UIP (b), mostly due to endothelial and inﬂammatory cell stain, but also to ﬁbroblast expression, Epithelial cells in FF are
more reactive than in COP. Nitrotyrosine reactivity is diﬀuse and intense in all COP cellular components (c). In UIP FF (d) nitrotyrosine
expression is limited to epithelial cells and inﬂammatory aggregates (upper right corner), while stromal cells are completely negative.
3.5. Clinicopathological Correlations. All UIP samples
showed advanced ﬁbrosis with architectural and temporal
heterogeneity and FF. FF number ranged between 3 and 12
per case and did not correlate with clinical and instrumental
parameters. Immunohistochemical stain results were similar
in terms of cell types expressing each markers and of
staining intensity within each disease group and showed no
correlation with disease severity.
4.Discussion
In the present study; we compared the proﬁle of expression
of oxidative stress marker, major antioxidant enzymes, and
mediators of ROS-induced cell activation in epithelial and
stromal cells of UIP FF, which inexorably progress to
irreversible lung ﬁbrosis, and of COP mesenchymal plugs,
that normally regress spontaneously or after steroid admin-
istration. The degree of RAGE expression was similarly high
in both conditions, while SODs and i-NOS were diﬀusely
present in COP, and almost absent in UIP FF. As far as
nitrosative stress is concerned,lower degrees of nitrotyrosine
were observed in UIP FF than in COP. Nitrotyrosine
colocalized with i-NOS in both conditions. These results
conﬁrm our previous observations, that documented RAGE
activation in UIP as well as in other lung pathologic condi-
tions[17].These observations are part oftheconﬂicting data
existing on RAGE involvement in human and experimental
lung ﬁbrosis. In contrast with our results, the pulmonary
expression of RAGE and of its soluble form sRAGE resulted
signiﬁcantly decreased in ﬁbrotic lungs in recent studies on
bleomycin-treated animals [18, 19], suggesting a protective
role for RAGE in pulmonary ﬁbrosis. Queisser et al. [18]
documented a reduced immunohistochemical expression
of RAGE in human UIP as compared to controls, and
suggested that the loss of RAGE in epithelial alveolar cells
and ﬁbroblasts of ﬁbrotic lungs is associated with disturbed
cellular contact and collagen adhesion, leading to ﬁbrosis
[18]. In contradiction to these data, other studies showed
that RAGE knock-out mice do not develop ﬁbrosis after
bleomycin administration, and that their type 2 alveolar
pneumocytes loose the capacity of undergoing EMT in
response to HMGB-1 [15]. The need of further studies
on RAGE function in pulmonary ﬁbrosis is clear from the
contrasting data reported and is justiﬁed by the development
of RAGE inhibition as a possible therapeutic target for
multiple conditions [20].
The results of the present paper are also in accordance
with recent studies showing reduced ECSOD levels in UIP
[6] and bleomycin animal models [21], and reduced i-NOS
levels in UIP [22, 23]. In vitro studies evidenced TGF-
β1-induced downregulation of SODs in alveolar epithelial
cells [6]. The authors [6] suggested that in ﬁbrotic lesions8 Pulmonary Medicine
antioxidantdownregulationreducestissuescavengingcapac-
ity and leads to the accumulation of ROS, which in turn
further induces TGF-β1 expression [12, 13, 24]. ROS genera-
tion in UIP FF can take place through the RAGE-NADPHox
pathway, which we showed to be overexpressed both in UIP
FF and in COP ﬁbroblastic plugs. The low expression of
SODs in UIP as compared to COP ﬁbroblast lesions could
contributeto explainthe diﬀerentbehaviorofthetwolesions
which otherwise bear a striking morphological similarity.
The hypothesis of an imbalanced oxidative stress has been
the rationale for the treatment of UIP patients with N-
acetylcysteine, which has so far showed promising but still
controversial results [25].
It has recently been proposed [26, 27] that bronchial
basal cells play a key role in the pathogenesis of UIP lesions.
These cellscan be recognized morphologically and immuno-
histochemically in a variable proportion of FF, where they
form an intermediate layer of large, squamoid cells, between
the alveolar epithelia and the ﬁbroblastic stroma, and
have for this reason been deﬁned as “sandwich foci” or
squamous metaplasia. In our experiments, we noticed that
epithelial cells of sandwich lesions were less reactive than
type II alveolar pneumocytes for RAGE and SODs, while the
degree of expression of i-NOS and nitrotyrosine was higher.
Although it is diﬃcult to say if such a slight diﬀerence of
expression can be functionally signiﬁcant, the interest of this
observation lays in the hypothesis that these cells are an
intermediate step in the epithelial-mesenchymal transition
from alveolar epithelia to ﬁbroblasts. The partial loss of
proteins normally expressed in epithelial cells and the de
novo acquisition of others could be a consequence of the
switch from the epithelial to the mesenchymal phenotype,
as documentedfor markers of cell adhesion and motility [27,
Morbini, submitted].
We ﬁnally analyzed the most relevant signal transduction
factors downstream of RAGE and TGF-β1a c t i v a t i o n .T h e
activation of RAGE increases ROS levels as a consequence
of enhanced NADPH oxidase activity. ROS are recognized
to mediate their signal through NF-κB and phosphorylated
SMAD2 nuclear transfer [10, 28]. TGF-β1 signaling is also
mediated through SMAD2 and SMAD3 phosphorylation
[29]. We unexpectedly observed ubiquitous nuclear expres-
sion of phosphorylated SMAD2 in all normal and patho-
logical samples, while NF-κB was expressed at a detectable
level only in inﬂammatory cells. This clear discrepancy
between the overexpression of RAGE in UIP ﬁbroblasts and
epithelial cells and the absence of expression of its main
signal transductor, in the absence of comparable literature
data, can be explained with expression levelsof NF-κBb e l o w
the threshold of immunohistochemical detection, or with a
rapid turnover that limits the amount of detectable protein.
Nuclear expression of SMAD3, a pivotal mediator of
TGF-β1a c t i v a t i o nl e a d i n gt oﬁ b r o s i s[ 30–32], was found
in a limited number of epithelial cells in UIP ﬁbroblastic
foci, while in COP diﬀuse cytoplasmic stain was observed
in multiple cell types. The pattern of stain was consid-
ered to be speciﬁc, since the antibody used in this study
stains both cytoplasmic unbound SMAD3 and the nuclear
SMAD3/SMAD4complex. To our knowledge, SMAD2and 3
expression has so far been documented in situ in bleomycin-
induced ﬁbrosis, and at the molecular and biochemical level
inhuman ﬁbroblasts,whilethecellularlocalizationofSMAD
proteins in human normal and ﬁbrotic lung has not yet
beendescribedwithinsitustudies.Ourobservationprovides
evidence of SMAD3 nuclear signaling in UIP lesions but
n o ti nC O Pﬁ b r o b l a s tp l u g sa n df u r t h e rc o n t r i b u t e st ot h e
evidence linking the activation of the TGF-β1-SMAD3 axis
to the developmentofpulmonary ﬁbrosis in UIP. The diﬀuse
nuclear expression of SMAD2 in normal and diseased lungs
is in accordance with the hypothesis that TGF-β1 signaling
through SMAD2 does not directly contribute to ﬁbrosis
[29, 33].
In conclusion,ourstudy showed that ﬁbroblast lesions of
UIP and COP share a similar degree of activation of the AGE
receptor and of its downstream mediators SMAD2 and NF-
κB, while antioxidant protein expression is higher in COP
than in UIP. Moreover, SMAD3 activation appears to be
speciﬁc of UIP lesions, thus conﬁrming the direct role of
TGF-β1 in their development. The described diﬀerences can
help to understand the causes of the irreversible progression
of UIP ﬁbrosis as compared to the prompt response to
steroid therapy ofﬁbroblastsplugs ofcryptogenicorganizing
pneumonia.
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